COMPANY OVERVIEW

Rafael Pharmaceuticals is pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer.

---

LOCATION

Newark, NJ, USA

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://rafaelpharma.com/

---

CAREER WEBSITE

https://rafaelpharma.com/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

May 19, 2022

Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.

Jan 18, 2022

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613 (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 6, 2022

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613 (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Dec 13, 2021

Rafael Pharmaceuticals Announces Published Data on CPI-613 (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 11, 2021

Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613 (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

For More Press Releases

---